Поиск по репозиторию
Статья
Strategies to Prevent SARS-CoV-2-Mediated Eosinophilic Disease in Association with COVID-19 Vaccination and Infection
2021
A vaccine to protect against COVID-19 is urgently needed. Such a vaccine should efficiently induce high-affinity neutralizing antibodies which neutralize SARS-CoV-2, the cause of COVID-19. However, there is a concern regarding both vaccine-induced eosinophilic lung disease and eosinophil-associated Th2 immunopotentiation following infection after vaccination. Here, we review the anticipated characteristics of a COVID-19 vaccine to avoid vaccine-associated eosinophil immunopathology. © 2020
Цитирование
Похожие публикации
Версии
- 1. Version of Record от 2021-04-27
Метаданные
Название журнала
- International Archives of Allergy and Immunology
Том
- 181
Выпуск
- 8
Страницы
- 624-628
Ключевые слова
- Fc receptor; immunoglobulin G antibody; immunoglobulin G1; immunoglobulin G3; neutralizing antibody; SARS-CoV-2 vaccine; toll like receptor affecting agent; COVID-19 vaccine; neutralizing antibody; virus vaccine; antibody production; cellular immunity; coronavirus disease 2019; eosinophil; eosinophilia; human; immune response; immunopathology; Loeffler pneumonia; lung infection; lymphocytic infiltration; mucosal immunity; nonhuman; priority journal; reinfection; Review; Severe acute respiratory syndrome coronavirus 2; vaccination; virus load; virus particle; adverse event; Betacoronavirus; biosynthesis; Coronavirus infection; immunology; pandemic; physiology; Th2 cell; vaccination; virus pneumonia; Antibodies, Neutralizing; Betacoronavirus; Coronavirus Infections; Eosinophils; Humans; Pandemics; Pneumonia, Viral; Th2 Cells; Vaccination; Viral Vaccines
Издатель
- S. Karger AG
Тип документа
- Review
Источник
- scopus
